Pay with

USD

Supports Visa, Mastercard, SEPA & more

Flexible trading, zero fees

Use your crypto for payments worldwide

Grow your wealth in fiat investment

Basic

Trade crypto freely

Magnify your profit with leverage

Convert & Auto-Invest

Trade any size with no fees and no slippage

Get exposure to leveraged positions simply

Pre-Market Trading

Trade new tokens before listing

Advanced

Trade on-chain with Gate Wallet

Smart access to new on-chain tokens

Smart strategies with automated trading

Follow expert trading strategies

CrossEx Trading

One margin balance, shared across platforms

Access hundreds of perpetual contracts

One platform for global traditional assets

Trade European-style vanilla options

Unified Account

Maximize your capital efficiency

Introduction to Futures Trading

Learn the basics of futures trading

Join events to earn rewards

Use virtual funds to practice risk-free trading

Stock CFD Derivatives

Access real US stocks and ETFs

Trade quality Hong Kong-listed stocks

Real Korean stocks and top assets

High leverage, 24/7 trading

Tokenized Stocks

Backed by real stock assets

Unlock full access to global stock IPOs

Mint GUSD for Treasury RWA yields

Stocks Activities

Trade Popular Stocks and Unlock Generous Airdrops

Launch

Collect candies to earn airdrops

Quick staking, earn potential new tokens

Hold GT and get massive airdrops for free

Unlock full access to global stock IPOs

Trade on-chain assets and earn airdrops

Earn futures points and claim airdrop rewards

Investment

Earn interest with idle tokens

Auto-invest on a regular basis

Dual Investment

Profit from market volatility

Earn rewards with flexible staking

Pledge one crypto to borrow another

One-stop lending hub

Premium wealth growth plans

Take control of your financial future

Top-tier quant strategies

Stake cryptos to earn in PoS products

No-liquidation leverage

Mint and Redeem Anytime, No Redemption Fees

Post, share, and explore crypto trends

Live crypto market analysis

Chat with crypto traders

What is happening in crypto

More

Promotions

Activity Center

Participate in activities to earn rewards

Invite friends to earn referral rewards

Affiliate Program

Earn exclusive commission rewards

Grow influence and earn airdrops

Real-time platform updates

Crypto industry articles

Huge fee discounts

Asset Management

One‑stop asset management solution

Enterprise digital asset solutions

Developers (API)

Connects to the Gate application ecosystem

OTC Bank Transfer

Deposit and withdraw fiat

Generous API rebate mechanisms

AI

Your all-in-one conversational AI partner

Use Gate AI directly in your social App

Gate Blue Lobster, ready to go

Gate for AI Agent

AI infrastructure, Gate MCP, Skills, and CLI

Gate Skills Hub

From office tasks to trading, the all-in-one skill hub makes AI even more useful.

Others

Find FAQs and help guides

Learn about crypto investing

Grow with the champions

Proof of Reserves

Gate promises 100% proof of reserves

Keep your assets secure

Rare Disease Drug Gets Approval in China Today, First Global Breakthrough for Multi-Center Developed Novel-Target Treatment

2026-07-21 06:45:28

According to China's NMPA, a novel-target drug for rare diseases received market approval in China today, marking a historic first for a globally synchronized multi-center developed treatment to achieve approval first in China rather than Western markets. The drug has simultaneously undergone review processes in multiple jurisdictions: it received breakthrough therapy designation and priority review status in China, breakthrough therapy designation and fast-track status in the United States, pioneer and orphan drug designations with expedited review in Japan, and orphan drug designation in the European Union.

Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.

Related News

China Approved 94 Cancer Drugs in 2020-25, Exceeding U.S. FDA's 87 Approvals

Citigroup Upgrades China Equities to Overweight in Emerging Markets Allocation

China's Four Authorities Strengthen Criminal Enforcement Against Fuel Pump Fraud on July 20

China Securities Regulator Holds Roundtable Today to Support Market Stability

China Securities Regulatory Commission Holds Stakeholder Meeting Tomorrow to Discuss Market Stability

In-Depth Analysis

Hanwha Engine and HD Hyundai Marine Engine Stocks Decline 50% Despite Record Orders

Lucas Bennett16h ago

US Government Considers Restrictions on Chinese AI Models After Kimi K3 Release

Oliver Grant16h ago

Korea Stocks Face MSCI Upgrade Challenge as Taiwan's Governance Reforms Set Benchmark

Lucas Bennett18h ago

Comment

0/400

No comments